Astra seeks EU okay for Seroquel XR in anxiety use

LONDON (Reuters) - AstraZeneca Plc is seeking European approval to sell its drug Seroquel XR as a treatment for anxiety, the Anglo-Swedish group said on Tuesday.

If approved, Seroquel XR would be the first atypical antipsychotic medicine cleared for the treatment of generalized anxiety disorder.

The European filing follows a similar U.S. submission in May and is part of a strategy to expand use of the medicine beyond schizophrenia.